文献速递银屑病与炎症性皮肤病

成人银屑病患者迈向生物制剂的历程:BioCAPTURE登记研究过去与现在结果

The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-12-26

本研究基于BioCAPTURE登记数据,回顾性描述重度银屑病患者从诊断到首次使用生物制剂的治疗特征。2005-2015年间患者中位使用传统系统药物时间(TUS)为11.0年,中位使用生物制剂时间(TUB)为18.9年,多数患者接受过三种不同传统系统治疗。2010-2015年相较2005-2009年有缩短趋势且生物制剂启动前传统系统药物种类减少,生物制剂启动后两年较前两年住院/日托入院显著减少(17.7 vs 8.6次/100随访年,P<0.001)。

要点

  • 重度银屑病患者启动生物制剂前中位病程长达18.9年,经历多种传统治疗。
  • 近年趋势显示生物制剂前传统系统药物种类减少,历程略有缩短。
  • 生物制剂启动后住院和日托入院次数显著下降。

核心结论

  • 银屑病患者通向生物制剂的旅程仍然漫长且以多种不同治疗为特征。
  • 观察到生物制剂启动前传统药物使用减少以及生物制剂前后住院和日托入院明显下降的趋势。

研究设计与样本

  • 探索性回顾性研究,基于BioCAPTURE登记中重度银屑病患者至首次生物制剂的治疗特征。
  • 采用描述性统计分析2005-2015年全部患者的治疗历程。
  • 比较2005-2009年与2010-2015年两个生物制剂处方时期的差异,并使用统计检验识别重要变化。

主要发现

  • 全部2005-2015年治疗患者中位TUS为11.0年,中位TUB为18.9年。
  • 多数患者接受过三种不同传统抗银屑病系统治疗。
  • 2010-2015年相较2005-2009年,有使用两种而非三种传统系统药物后启动生物制剂的小趋势。
  • 生物制剂启动前两年与启动后头两年相比,住院/日托入院显著减少(17.7 vs 8.6次/100随访年,P<0.001)。
  • 环孢素、强效局部治疗(地蒽酚)、维A酸类和PUVA治疗近年受欢迎程度下降。

关键数值与推荐

  • 中位TUS为11.0年,中位TUB为18.9年(2005-2015年全部患者)。
  • 多数患者接受过三种不同传统抗银屑病系统治疗。
  • 生物制剂启动前两年vs后头两年入院率:17.7 vs 8.6次/100随访年,P<0.001。

临床怎么用

  • 临床应关注银屑病患者启动生物制剂前的漫长治疗历程,尤其年轻或新诊断患者。
  • 改善该历程可能减少对患者生活的负面影响并降低社会影响。
  • 生物制剂治疗与住院和日托入院减少相关,可考虑用于重度患者以降低医疗资源使用。

局限性

  • 探索性回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 数据来自单一登记,外部推广性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A considerable disease period often precedes initiation of a biologic in patients with psoriasis. Little is known about this important period in patients' lives. Evaluation of this 'journey' can reveal important insights and opportunities for physicians and healthcare decision makers. OBJECTIVES: (i) To describe patient and treatment characteristics until the start of biologic treatment in patients with severe psoriasis, (ii) to assess shifts in early (2005-2009) versus established (2010-2015) biologics prescription periods, (iii) to assess changes in hospital/day care admissions before vs. after starting biologics. METHODS: Explorative, retrospective study on the treatment characteristics of the disease period until first biologic, presented with descriptive statistics of patients included in the BioCAPTURE registry. Journeys of 2005-2009 and 2010-2015 were compared with statistical tests to identify important shifts. RESULTS: Median TUS (time until conventional systemic) was 11.0 years and median TUB (time until biologic) was 18.9 years for all patients treated from 2005 to 2015. Most patients received three different conventional antipsoriatic systemic therapies. We noticed a small trend towards a shorter journey (TUB) with only two conventional systemic agents instead of three before initiating a biologic in later years (2010-2015, vs. 2005-2009). We also noticed a significant decrease in (day care) admissions comparing the two years before, versus the first two years after the start of a biologic treatment (17.7 vs. 8.6 admissions/100 follow-up years, P < 0.001). Cyclosporine, intensive topical treatment (dithranol), retinoids and PUVA therapy lost popularity in recent years. CONCLUSION: The 'journey' of patients with psoriasis towards a biologic is still long and characterized by many different treatments. Shifts towards fewer conventional drugs before biologic initiation and a clear decrease in hospital and day care admissions before vs. after a biologic are seen. Improvement of this journey, especially in young or recently diagnosed patients, can decrease negative influences on patients' lives and reduce societal impact.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. van den Reek JMPA, Seyger MMB, van Lümig PPM, et al. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2017. PMID: 29121430. doi:10.1111/jdv.14684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。